Fluorouracil (5-FU): Dosing, Indications, and Precautions
Fluorouracil is administered systemically via intravenous routes (bolus or continuous infusion) for various solid tumors, with specific dosing regimens varying by cancer type, and topically for dermatologic conditions including actinic keratosis and superficial basal cell carcinoma.
Systemic Administration
Colorectal Cancer
For metastatic colorectal cancer, the backbone of chemotherapy consists of fluoropyrimidine-based regimens 1, 2. The most commonly used systemic regimens include:
FOLFOX (with leucovorin and oxaliplatin): 5-FU 400 mg/m² IV bolus on day 1, followed by 1200 mg/m²/day × 2 days (total 2400 mg/m² over 46-48 hours) as continuous infusion, repeated every 2 weeks 3
FOLFIRI (with leucovorin and irinotecan): Similar 5-FU dosing as FOLFOX 3
Simplified biweekly regimen (sLV5FU2): Leucovorin 400 mg/m² IV over 2 hours on day 1, followed by 5-FU bolus 400 mg/m² then 1200 mg/m²/day × 2 days continuous infusion, repeated every 2 weeks 3
Critical safety note: NCCN recommends limiting chemotherapy orders to 24-hour units (i.e., 1200 mg/m²/day NOT 2400 mg/m²/day over 46 hours) to minimize medication errors 3.
Infused regimens are less toxic than bolus regimens and should be preferentially used 4. FOLFOX and FOLFIRI have similar activity but different toxicity profiles: more alopecia and diarrhea with irinotecan versus more polyneuropathy with oxaliplatin 4, 1.
Anal Squamous Cell Carcinoma
For stage I-III anal cancer, mitomycin-C (MMC) with fluorouracil is the recommended radiosensitizing regimen 5:
MMC + 5-FU: MMC 10 mg/m² (max 20 mg) on day 1 and day 29, with 5-FU 1,000 mg/m² continuous infusion on days 1-4 (week 1) and 29-32 (week 5) 5
Alternative (cisplatin contraindication): Cisplatin 60 mg/m² on days 1 and 29 with 5-FU 1,000 mg/m² continuous infusion days 1-4 and 29-32 5
The second dose of mitomycin on day 29 is associated with additional toxicity and should be used with caution 5. For immunosuppressed patients, avoid MMC due to increased myelosuppression risk; use cisplatin-based regimens instead 5.
Pancreatic Adenocarcinoma
The recommended dose is 400 mg/m² IV bolus on day 1, followed by 2400 mg/m² as continuous infusion over 46 hours every 2 weeks, administered with leucovorin or as part of a multidrug regimen 6.
Breast Cancer
5-FU is used in combination regimens such as fluorouracil-epirubicin-cyclophosphamide (FEC) or fluorouracil-doxorubicin-cyclophosphamide (FAC) for adjuvant therapy 7. Classic cyclophosphamide-methotrexate-fluorouracil (CMF) with oral cyclophosphamide days 1-14 and IV methotrexate-fluorouracil days 1 and 8, repeated every 28 days for six cycles, is an acceptable alternative when anthracycline-taxane regimens are contraindicated 7.
Topical Administration
For actinic keratosis, topical 5-FU is strongly recommended as field-directed therapy 8. The drug is applied as a cream, gel, or solution directly to affected areas, typically twice daily for several weeks. Topical 5-FU is FDA-approved for actinic keratosis and superficial basal cell carcinoma 9, 10.
Systemic absorption of topical 5-FU is minimal (approximately 5-6% of applied dose), with negligible plasma concentrations 9. Recent evidence shows topical 5-FU achieves 96.4% complete clearance for squamous cell carcinoma in-situ as primary therapy and 92.3% clearance as adjuvant therapy post-Mohs surgery 11.
Critical Precautions and Contraindications
DPD Deficiency Testing
Patients with complete dihydropyrimidine dehydrogenase (DPD) deficiency are at extreme risk for fatal toxicity, and fluorouracil is not recommended in this population 6. Consider genetic testing for DPYD variants prior to initiating therapy when clinically feasible 6. Patients with partial DPD deficiency may require dose reductions, though no specific safe dose has been established 6.
Mandatory Dose Holds
Withhold fluorouracil immediately for 6:
- Cardiotoxicity (angina, myocardial infarction/ischemia, arrhythmia, heart failure)
- Hyperammonemic encephalopathy
- Acute cerebellar syndrome, confusion, disorientation, ataxia, or visual disturbances
- Grade 3-4 diarrhea
- Grade 2-3 palmar-plantar erythrodysesthesia (hand-foot syndrome)
- Grade 3-4 mucositis
- Grade 4 myelosuppression
There is no recommended dose for resumption following cardiac toxicity, hyperammonemic encephalopathy, or neurologic toxicity 6. For other toxicities, resume at reduced dose only after resolution to Grade 1 or less 6.
Cardiotoxicity Risk
Continuous infusion carries higher cardiotoxicity risk than bolus administration, particularly in patients with pre-existing coronary artery disease 6. Cardiotoxicity can manifest as angina, myocardial infarction, arrhythmia, or heart failure based on postmarketing reports 6.
Administration Route Matters
Continuous infusion has significantly lower myelotoxicity risk compared to IV bolus despite higher total doses 12. This is due to pharmacokinetic differences in bone marrow exposure. For infusion regimens, administer through a central venous line using an infusion pump 6.
Hepatic Arterial and Intraperitoneal Routes
While parenteral IV administration is standard, hepatic arterial infusion and intraperitoneal administration are clinically feasible alternatives with pharmacokinetic rationale for specific indications 13.
Common Pitfalls
Medication errors: Always order continuous infusions in 24-hour increments to prevent dosing errors 3
Geographic toxicity variation: North American patients experience greater toxicity with fluoropyrimidines than European patients and may require lower doses, particularly with capecitabine combinations 3
Overlooking DPD deficiency: Early-onset severe toxicity (mucositis, diarrhea, neutropenia within 72 hours) suggests DPD deficiency—withhold immediately 6
Inadequate monitoring: Despite standard dosing (Mayo regimen: 425 mg/m²/day × 5 days every 4-5 weeks), 35% of patients experience prohibitive toxicity requiring dose modification, with no clinical characteristics reliably predicting toxicity 14
Combination with other agents: Do not administer concomitantly with other medications in the same IV line 6
Storage and Preparation
Store undiluted fluorouracil in syringe for up to 4 hours at room temperature (25°C) for bolus administration 6. Diluted solutions may be stored up to 4 hours at room temperature prior to patient administration 6. Pharmacy bulk packages must be discarded 4 hours after penetration of container closure 6.